Phair Pricing Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Feb 7, 2019)
Phair Pricing Act of 2019
This bill requires that certain negotiated prices for covered drugs under the Medicare prescription drug benefit be disclosed at the point-of-sale.
Specifically, negotiated prices offered under a prescription drug plan (PDP) must be disclosed at the point-of-sale; the disclosed price must include specified adjustments, payments, and fees that are negotiated with the pharmacy (e.g., dispensing fees) by the PDP sponsor or pharmacy benefit manager.
Additionally, the Centers for Medicare & Medicaid Services must establish certain quality measures for PDP sponsors to use when determining incentive payments and adjustments (e.g., performance payments) to pharmacies.
What just happenedFeb 7, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseFeb 7, 2019
- Feb 7, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Feb 7, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Feb 7, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Feb 7, 2019IntroReferralIntro-H
Introduced in House
- Feb 7, 2019IntroReferral1000
Introduced in House